Induction of supra-ventricular arrhythmias dobutamine vs isoprotrenole

arrhythmia Induction using isoproterenol or dobutamine during electrophysiology study for supra-ventricular arrhythmia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230918059453N1

Enrollment

500

Registered

2023-10-16

Start date

2023-12-22

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiac arrhythmia, unspecified. Cardiac arrhythmia, unspecified

Interventions

Intervention 1: Intervention group 1: Dobutamine - by injection once at the beginning of the study. At the beginning of the study, 15 micrograms of dobutamine drug were injected to the people in this

Eligibility

Sex/Gender

All

Age

18 Years to 90 Years

Inclusion criteria

Inclusion criteria: All patients underwent ablation

Exclusion criteria

Exclusion criteria: All patients are included in the study and there are no conditions for non-entry.

Design outcomes

Primary

Measure	Time frame
Recurrence arrhythmia. Timepoint: 1, 3, and 6 months after the intervention. Method of measurement: Based on recurrence of arrhythmia and need to anti arrhythmic drug or ablation.	—

Secondary

Measure	Time frame
Recurrence of chest pain and arrhythmia. Timepoint: 1,3,6 mount. Method of measurement: underwent ECG by cardiologist.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactLeila Jamali

Shiraz University of Medical Sciences

jamalileila1989@gmail.com+98 71 3212 2320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026